Eris Lifesciences Limited

ERIS.BO·BSE·Healthcare
Compare
1,135.55+9.85 (+0.88%)today
At close: Oct 21, 3:27 PM IST · May be delayed up to 15 min · INR

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close1,125.70
Open1,119.90
Day range1,115.001,146.05
52-week range1,114.251,737.00
Off day high−0.92%
Off 52-week high−34.63%
Volume57.17K
Avg. volume (3M)26.40K
Market cap157.54B
EPS (TTM)46.96
Forward P/E19.68
P/E ratio (TTM)24.18
Dividend yield1.28% (14.42)
Beta (5Y)-0.03
Shares outstanding138.74M
Short interest—
Earnings dateJul 31, 2025 (est.)
Analyst target1,632.20
Profit margin20.04%

Against its peers

Compare in full ›
ERIS.BO ZYDUSLIFE.BO EMCURE.BO SOBI.ST NBIX IPCALAB.BO
Market cap 157.54B 1.11T 333.12B 156.39B 14.43B 486.30B
P/E (TTM) 24.2 24.9 32.9 117.0 20.8 37.1
Forward P/E 19.7 22.7 22.6 28.9 11.9 27.2
Price/book 4.0 4.1 6.7 3.7 3.9 6.0
Dividend yield 1.28% 0.09% 0.20% — — 0.33%
1-year change −29.18% +10.44% +27.60% +38.35% +0.37% +42.82%
Today +0.88% +0.39% −0.52% +0.63% +3.66% +5.60%

The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 15 min.

Latest news

All ERIS.BO news ›
Express Pharma·Positive

Eris Lifesciences appoints Chirag Mehta as Executive Director

Eris Lifesciences has announced the appointment of Chirag Mehta as Executive Director. He will be based at the company’s Mumbai office and will report to the CMD. In his non-statutory executive role, Mehta will oversee Finance, Investor…

From articles in the 4Search news index.

In the news

7mentions in 30 days
7with it in the headline
Positivesentiment

Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 7 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4Search index. Terms of use.